Autoimmune Disease Drugs
- Anti-Ulcerants
- Antibacterials
- Antibiotics
- Anticoagulants
- Antidiabetics
- Antifungals
- Antivirals
- Autoimmune Disease Drugs
- Biologics
- Biosimilars
- Cardiovascular Drugs
- Cellular Therapeutics
- Combination Therapies
- Dermatologic Drugs
- Enzyme Replacement Therapy
- Generics
- Hormone Replacement Therapy
- Immuno-oncology
- Immunotherapies
- Lipid Regulators
- Mental Health Drugs
- Oncologics
- Orphan Drugs
- Pain
- Protein Therapeutics
- Psychoactive Drugs
- Radiopharmaceuticals
- Respiratory Drugs
- Traditional Chinese Medications
- Vaccines
![GlaxoSmithKline (GSK) has made a $300 million equity investment in 23andMe under a collaboration designed to accelerate development of new therapies for both companies by using genetic data to identify new drug targets. [Source: © fotoliaxrender/Fotolia]](https://www.genengnews.com/wp-content/uploads/2018/08/Aug5_2014_56448122_DNAblue_NovelDiagnosticGenomic12114111424-265x198.jpg "GSK Invests $300M in 23andMe as Companies Collaborate on Drug Development")
![This confocal microscopic image of a healthy mouse T cell uses color florescence to illustrate how the protein Gimap5 (upper-right faint green area) and the enzyme GSK3 (red) overlap in small structures called vesicles inside cells (colocalized yellow area). This happens before GSK3 enters the cell nucleus (shown in blue). This step is important to limit DNA damage in active T cells during their expansion. The image is part of a study published Jan. 30 by Nature Communications from researchers at Cincinnati Children's. [Cincinnati Children's]](https://www.genengnews.com/wp-content/uploads/2018/08/Jan30_2018_CincinnatiChildrens_TCellRegulator1019210011-324x160.jpg "Immune Disorder Trigger Identified")
